Rose McNulty

An interim analysis of the KEYNOTE-716 trial of adjuvant pembrolizumab supports its use in the adjuvant setting for patients with resected melanoma.

Recent research used incidence and mortality data from the GLOBOCAN 2020 database to gain insight into worldwide patterns of non-Hodgkin lymphoma in 2020.

A recent review summarized the current knowledge and treatment paradigm of multiple myeloma, including recent advances and challenges in nanomedicine. 

Transfusion dependence is common for patients with myelodysplastic syndromes (MDS), but real-world data show inconsistent patient experiences and varied transfusion practices between countries.

Major adverse cardiac events are rare but serious in patients treated with immune checkpoint inhibitors (ICIs), and increased awareness is crucial to identify and treat these conditions in a timely manner.

Immune checkpoint inhibitors have changed the way certain cancers are treated, but more can be done to optimize treatment and improve patient responses.

A recent meta-analysis aimed to clarify the relationship between parental age and solid tumor pediatric cancers, but more studies are necessary to overcome the limitations of available research.

While no agents are approved just yet, a variety of promising drugs targeting CLDN18.2 are undergoing early research and clinical trials for several cancer types. 

Findings of a study on children and adolescents with type 1 diabetes (T1D) in Italy suggest lockdown periods during COVID-19 did not increase disordered eating symptoms or adversely affect disease management.

Finding therapeutic targets for acute myeloid leukemia (AML) has proven challenging, but a set of immune-regulating molecules may hold promise as biomarkers and targets.

A novel prognostic model based on N 6-methyladenosine-associated long non-coding RNAs demonstrated accuracy in determining high- and low-risk disease, suggesting the associated risk value may have potential as a novel biomarker.

Preventing graft-versus-host disease (GVHD) after allogeneic stem cell transplant is a key aspect of patient management, but current cyclosporine concentration guidelines may not be sufficient, according to a recent study.

A retrospective study found low treatment adherence and no significant benefits to adjuvant chemotherapy or chemoradiotherapy following cholangiocarcinoma resection.

A recent study aimed to provide insight and guidance for managing graft-versus-host disease in patients after liver transplantation.

Whole-exome sequencing of a family with early-onset cancers found a novel variant in programmed cell death 1 ligand 2 that could potentially indicate germline predisposition to lymphoma.

A recent review points to a host of potentially disease-modifying agents currently in clinical trials.

Recurrence is common in patients with distal cholangiocarcinoma, even after curative surgical resection. In a recent study, postoperative adjuvant therapy correlated with improved survival, but only in certain patients.

Patients being treated for acute myeloid leukemia (AML) who are diagnosed with COVID-19 may be best served by chemotherapy delay until after COVID-19 has run its course.

A small study aimed to increase the likelihood of detecting minor neurological symptoms of spinal muscular atrophy via a combination of tests specifically suited to newborns.

A survey of blood and bone marrow transplant patients found that many who fit current criteria for ocular graft-versus-host disease have not been diagnosed.

A recent study identified TIGIT as a marker of chimeric antigen receptor (CAR) T-cell exhaustion and found it to improve CAR T-cell therapy efficacy in preclinical models.

Differentiation between multiple myeloma (MM) and bone metastases from other cancers can be difficult, but radiomics-based models have potential to improve diagnostic accuracy.

Treatment resistance is a significant challenge in immunotherapy, but it is not fully understood. A recent review summarized 5 tumor microenvironment traits that may inhibit therapy effectiveness and potential strategies to improve therapy responses.

While 5-year survival in adolescent and young adult leukemia has improved in recent decades, this patient population still faces increased long-term mortality compared with the general public.

Fine-tuning clinical phenotypes and identifying effective treatments remain challenging in chronic lung allograft dysfunction (CLAD) after lung transplantation and chronic graft-versus-host disease (GVHD) after allogeneic hematopoietic stem-cell transplantation.

Locally advanced or metastatic basal cell carcinoma can be challenging to treat, but programmed death receptor 1 inhibition may hold potential as a tolerable, effective approach in patients of all ages.

Significant progress has led to improved survival in patients with HIV/AIDS, but lymphoma remains a leading cause of morbidity and mortality in this patient population.

A retrospective study assessed hospital readmission rates in patients with sickle cell disease and acute chest syndrome who took angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers vs those who did not.

Improved management of sickle cell disease has vastly improved life expectancy and reduced morbidity for affected patients, but the disease itself and its treatments carry fertility risks that many young patients and their caregivers are unaware of.

Very elderly patients with acute myeloid leukemia have historically been limited to less intensive, less effective treatment regimens. A recent series of cases suggests age alone should not be a limiting factor for effective treatment.